The ruthenium-catalyzed azide alkyne cycloaddition (RuAAC) affords 1, 5-disubstituted 1, 2,
3-triazoles in one step and complements the more established copper-catalyzed reaction …

Factor XIa (FXIa) in the intrinsic pathway of the coagulation process has been proven to be
an effective and safe target for anticoagulant discovery with limited or no bleeding …

Coagulation factor (F) XI has been described as a component of the early phase of the
contact pathway of blood coagulation, acting downstream of factor XII. However, patients …

Abstract Factor XIa (FXIa) is a serine protease homodimer that belongs to the intrinsic
coagulation pathway. FXIa primarily catalyzes factor IX activation to factor IXa, which …

Introduction: Anticoagulants are the mainstay for prevention and/or treatment of thrombotic
disorders. Each clinically used anticoagulant is associated with significant adverse …

Growing evidence suggests that plasmin is involved in a number of physiological processes
in addition to its key role in fibrin cleavage. Plasmin inhibition is critical in preventing …

The Cu (I)-catalyzed azide-alkyne cycloaddition reaction, also known as click chemistry, has
become a useful tool for the facile formation of 1, 2, 3-triazoles. Specifically, the utility of this …

Factor XI (FXI), the zymogen of activated FXI (FXIa), is an attractive target for novel
anticoagulants because FXI inhibition offers the potential to reduce thrombosis risk while …

We recently introduced sulfated pentagalloylglucopyranoside (SPGG) as an allosteric
inhibitor of factor XIa (FXIa)(Al-Horani et al., J. Med Chem. 2013, 56, 867–878). To better …

Highlights•Factor XI is the precursor of a plasma protease (factor XIa) that contributes to
normal blood coagulation (hemostasis).•Factor XIa contributes to thrombosis in humans.•In …